MULTICENTER SECOND LINE STUDY OF AXITINIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) PROGRESSED WITH SORAFENIB STUDIO CLINICO MULTICENTRICO DI SECONDA LINEA DI AXITINIB IN PAZIENTI CON CARCINOMA EPATOCELLULARE (HCC) IN PROGRESSIONE DOPO TERAPIA CON SORAFENIB

Trial Profile

MULTICENTER SECOND LINE STUDY OF AXITINIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) PROGRESSED WITH SORAFENIB STUDIO CLINICO MULTICENTRICO DI SECONDA LINEA DI AXITINIB IN PAZIENTI CON CARCINOMA EPATOCELLULARE (HCC) IN PROGRESSIONE DOPO TERAPIA CON SORAFENIB

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2014

At a glance

  • Drugs Axitinib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top